The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?
The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics.
Sellers
William R
WR
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. william_sellers@dfci.harvard.edu
Loda
Massimo
M
D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D000071221:Enhancer of Zeste Homolog 2 Protein; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D063151:Polycomb Repressive Complex 2; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000556:secondary* / Q000601:surgery; D011506:Proteins / Q000032:analysis / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics* / Q000502:physiology*; D014157:Transcription Factors; D014158:Transcription, Genetic; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D011506:Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; D014157:Transcription Factors; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2